Life sciences briefing: Monday, Nov. 12, 2007
(UPDATED: See below.)
Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals
UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.
Antibody-drug maker Raven Biotech merges with VaxGen — Raven Biotechnologies, a South San Francisco biotech developing antibody drugs, is merging with the troubled, publicly held vaccine maker VaxGen. The confusingly worded release is here.
Although… Continue Reading
DiBcom receives $27 million more to get dibs on mobile TV market
The mobile TV market is expected to have more than 130 million customers by 2011, according to Screen Digest.
So DiBcom, a France-based semiconductor-for-mobile-tv company has received another $27 million in funding from its many investors, this time adding French bank NATIXIS. The company says it will use the money to continue improving its TV-streaming technology, and to spread faster internationally to phones, laptops, cars and other devices around the world.
We’re speculating that the company timed… Continue Reading